FDAnews Drug Daily Bulletin

HELIX BIOMEDIX REPORTS 2005 FINANCIAL RESULTS

March 29, 2006
A A

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the year ended December 31, 2005. For 2005, Helix BioMedix reported a net loss of $3,277,239, or $0.18 per diluted share, compared to a net loss of $3,109,274, or $0.23 per diluted share, in the comparable prior year period. Revenue for 2005 was $108,408 compared to $93,661 for 2004. Revenue for 2006 will be dependent on the sales of products that incorporate the company's peptides as well as Helix BioMedix's ability to enter into collaborative or licensing agreements with third parties.
PR Newswire